Targazyme
Tom is concurrently the CBO of Taiwan Liposome. Tom was previously the former CEO of Genisphere, VP of Business Development at Baxter, Head of the Business Development Group at Amgen where he directed all M&A and Licensing operations, and Johnson & Johnson where he was in charge of licensing projects. He was at Donaldson, Lunin & Jenreje New York as Vice President, Biotech Corporate Finance where he led multiple life sciences debt/equity financings, IPO, and acquisition advisory projects. Tom received his MBA from the Wharton School of Management, University of Pennsylvania, and Bachelor of Arts Degree from Dartmouth College.
This person is not in any teams
This person is not in any offices
Targazyme
Targazyme Inc. is a San Diego-based, clinical-stage biopharmaceutical company developing novel enzyme-based platform technologies and products to improve clinical efficacy and cost of care outcomes for cell therapy, immunotherapies for autoimmune diseases and cancer, stem cell transplantation, gene therapy and regenerative medicine.